SAMHD1 has recently been proposed as a potential tumor suppressor, and in fact, many FDA-approved anti-cancer TKIs have potent effects on SAMHD1 activation in vitro and in vivo (29, 30, 44). Here, SAMHD1 is linked to cancer.